Pasar al contenido principal

NUEVA GENERACION DE INMUNOTERAPIAS CONTRA CANCER BASADAS EN LINFOCITOS ENTRENADOS CON BACTERIAS

PID2020-116393RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacteria-instructed B cells cross-prime naïve CD8+ T cells triggering effective cytotoxic responses

  • García-Ferreras, Raquel
  • Osuna-Pérez, Jesús
  • Ramírez-Santiago, Guillermo
  • Méndez-Pérez, Almudena
  • Acosta-Moreno, Andrés M.
  • Del Campo, Lara
  • Gómez-Sánchez, María José
  • Iborra Pernichi, Marta
  • Herrero-Fernández, Beatriz
  • González-Granado, Jose M.
  • Sánchez-Madrid, Francisco
  • Carrasco, Yolanda R.
  • Boya, Patricia
  • Martínez-Martín, Nuria
  • Veiga, Esteban
In addition to triggering humoral responses, conventional B cells have been described in vitro to cross-present exogenous antigens activating naïve CD8 T cells. Nevertheless, the way B cells capture these exogenous antigens and the physiological roles of B cell-mediated cross-presentation remain poorly explored. Here, we show that B cells capture bacteria by trans-phagocytosis from previously infected dendritic cells (DC) when they are in close contact. Bacterial encounter “instructs” the B cells to acquire antigen cross-presentation abilities, in a process that involves autophagy. Bacteria-instructed B cells, henceforth referred to as BacB cells, rapidly degrade phagocytosed bacteria, process bacterial antigens and cross-prime naïve CD8 T cells which differentiate into specific cytotoxic cells that efficiently control bacterial infections. Moreover, a proof-of-concept experiment shows that BacB cells that have captured bacteria expressing tumor antigens could be useful as novel cellular immunotherapies against cancer., The research is supported by grants: SAF2017-84091-R, and PID2020-116393RB-I00/AEI/10.13039/501100011033, financed by MCIN,BFERO2020.04, financed by FERO foundation and PI20/0036 from ISCIII. RGF issupported by BES-2016-076526 from the Spanish Ministry of Economy Industry and Competitiveness, JOP is supported by fellowship LCF/BQ/SO16/52270012 fromLa Caixa, BHF is supported by FPU18/00895 and AMP by FPU18/03199 from Ministry of Science, Innovation and Universities. LdC hasbeen supported by Juan de la Cierva grant IJC2018-035386-I and a contractas sociated to SEV-2017-0712. EVC, AMP, AMAM, and NMM belong to the Span-ish National Research Council (CSIC)’s Cancer Hub
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Unraveling the power of NAP-CNB's machine learning-enhanced tumor neoantigen prediction

  • Méndez-Pérez, Almudena
  • Acosta-Moreno, Andres M.
  • Wert-Carvajal, Carlos
  • Ballesteros-Cuartero, Pilar
  • Sánchez-García, Ruben
  • Macias, José Ramón
  • Sanz-Pamplona, Rebeca
  • Alemany, Ramon
  • Sorzano, Carlos Óscar S.
  • Munoz-Barrutia, Arrate
  • Veiga, Esteban
In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies., The research is supported by grants: PID2020-­ 116393RB-­ I00, financed by MCIN/ AEI/10.13039/501100011033/and BFERO2020.04, financed by FERO foundation. AMP is supported by FPU18/03199JMGG from MCIN. We are grateful to the Proteomics and the Animal Facilities of CNB for peptide synthesis and their support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Plasmid sequences and maps [Dataset]

  • Méndez-Pérez, Almudena
  • Veiga, Esteban
Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI) 10.13039/501100011033. Grant PID2023-148725OB-I00 Ministerio de Ciencia e Innovación (MCI)and AEI/10.13039/501100011033, grant PID2020-116393RB-I00, 1.1 pGEN22 NA LLO Map.pdf 1.2 pGEN22 NA LLO.dna 1.3 pGEN22 NA LLO.fa 2.1 pGEN22 TRP2 LLO Map.pdf 2.2 pGEN22 TRP2 LLO.dna 2.3 pGEN22 TRP2 LLO.fa 3.1 pGEN22-OVA-LLO Map.pdf 3.2 pGEN22-OVA-LLO.dna 3.3 pGEN22-OVA-LLO.fa 4.1 pPL2 NA Map.pdf 4.2 pPL2 NA.dna 4.3 pPL2 NA.fa, Peer reviewed